Showing Results for: “Contact ”

Learn how to address diabetes-related challenges at school, including resolving accommodation issues, advocating for your child's rights, and working with school staff to ensure a safe learning environment.

As Louisiana braces for Tropical Storm Barry, a potential hurricane that is currently expected to make landfall on Friday, the diabetes community is rallying to make sure that people living with diabetes—especially those who depend upon insulin—are fully supported. The Diabetes Disaster Response Coalition (DDRC), which is comprised of the nation’s leading diabetes organizations, is urging all people with diabetes and their loved ones to prepare by putting together a diabetes kit and making a plan to stay healthy and safe during the storm and in its aftermath. The DDRC has created a Patient

For people with type 2 diabetes (T2D) and chronic kidney disease (CKD), canagliflozin, an oral, sodium-glucose co-transporter-2 (SGLT2) inhibitor, has a renal- and cardiovascular-protective effect in reducing the progression of kidney impairment, according to the results of the CREDENCE trial presented today in a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. In the first of several renal outcomes studies of SGLT2s, the landmark Canagliflozin and Renal Events in Diabetes with Established Nephropathy

People with impaired glucose tolerance (IGT) may significantly lower their risk of cardiovascular disease (CVD) and microvascular disease by delaying the onset of type 2 diabetes (T2D) by six years or more, or by returning to a normal level of glucose tolerance altogether, according to the study, “Early Progression to Diabetes or Regression to Normal Glucose Tolerance Among People with Impaired Glucose Tolerance Affects Long-Term Outcomes: Thirty-Year Follow-Up of Da Qing Diabetes Prevention Study,” presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at

Building on 18 months of proven success, the initiative will scale evidence-based solutions to improve pregnancy and postpartum outcomes for New Yorkers The CVS Health Foundation granted the American Diabetes Association® (ADA) $2.6 million to expand its maternal health initiative to two additional communities within New York City. This expansion builds on the tremendous success of the program’s first 18 months, which improved early gestational diabetes (GDM) screening and care coordination for hundreds of patients at Wyckoff Heights Medical Center in Brooklyn. The next phase will bring these

Prevalence of diabetes disproportionately impacted lower-income populations; highlights the need for increased prevention strategies A new study from researchers at the Centers for Disease Control and Prevention (CDC) reveal income-related inequalities (IRI) in rates of diabetes exist between 2001 and 2018. The findings were presented at the virtual 81st Scientific Sessions held by the American Diabetes Association ® (ADA). Throughout the U.S., diabetes prevalence has increased over the past two decades, disproportionately affecting low-income populations. For example, between 2011 and 2014

Initial data indicate that children presented with higher acuity compared to the previous year New data show that the incidence and acuity of type 2 diabetes in children increased significantly during the peak of the COVID-19 pandemic, with more pediatric patients hospitalized from March to December 2020 compared to the same time period in 2019. Findings from the retrospective chart review were presented as a late-breaking poster session at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Stay-at-home orders due to the COVID-19 pandemic exacerbated risk

VERTIS-CV trial of SGLT2 inhibitor evaluated medication’s cardiovascular safety in patients with type 2 diabetes and heart disease The sodium glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin does not impact the likelihood of heart attack, stroke, or cardiac death in patients with type 2 diabetes (T2D) and established cardiovascular (CV) disease, according to data presented today. Research also showed the rate of hospitalization for heart failure was lower among study participants treated with ertugliflozin. The study was highlighted during the “Results of the eValuation of

Veterans Health Administration program combining telemonitoring, self-management and medication support improves HbA1c levels within six months In a project entitled “Implementation of Intensive Telehealth Intervention for Rural Patients with Uncontrolled Diabetes,” researchers revealed improved HbA1c levels among rural patients with poorly-controlled type 2 diabetes who participated in a comprehensive telehealth program. The results were presented today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions®. The study found a 1.36% reduction in HBA1c levels after

Consensus report outlines the positive impact of diabetes self-management education and support and the critical need for increased access Seven leading diabetes organizations issued a consensus report today highlighting the value of diabetes self-management education and support (DSMES) services as part of comprehensive diabetes medical care. The report provides compelling evidence for the need for increased utilization of DSMES, four key times that DSMES is most beneficial, and specific recommendations for both clinicians and health systems to increase access to and participation in DSMES